\-\ Texto\\:\\ \ \(0\)\
\-\ axillary\\ lesions\\:\\ multiple\\ 2\\-3mm\\ hyperpigmented\\ macules\\ in\\ the\\ bilateral\\ axilla\\.\ \(0\)\
\-\ upper\\ extremities\\ and\\ back\\ with\\ large\\ hyperpigmented\\ macules\\ and\\ patches\\ in\\ various\\ size\\ consistent\\ with\\ caf\\?\\ au\\ lait\\ spots\\.\ \(0\)\
\-\ lower\\ extremities\\:\\ large\\ 18\\ x\\ 9cm\\ boggy\\ hyperpigmented\\ plaque\\ on\\ the\\ left\\ lateral\\ thigh\\.\\ it\\ has\\ a\\ \\"bag\\ of\\ worms\\"\\ feel\\ and\\ is\\ moderately\\ tender\\ on\\ palpation\\.\ \(0\)\
\-\ the\\ patient\\ was\\ advised\\ to\\ follow\\ up\\ with\\ her\\ obgyn\\ for\\ routine\\ pregnancy\\ care\\.\\ there\\ is\\ no\\ specific\\ treatment\\ for\\ neurofibromatosis\\ type\\ 1\\,\\ but\\ routine\\ surveillance\\ for\\ complications\\ is\\ recommended\\.\\ the\\ patient\\ was\\ counseled\\ to\\ seek\\ follow\\ up\\ with\\ an\\ ophthalmologist\\ for\\ a\\ full\\ eye\\ exam\\ and\\ to\\ maintain\\ regular\\ follow\\ ups\\ with\\ her\\ primary\\ care\\ physician\\.\\ there\\ is\\ the\\ potential\\ for\\ large\\ plexiform\\ lesions\\ to\\ undergo\\ malignant\\ degeneration\\ which\\ could\\ present\\ as\\ rapid\\ change\\ in\\ size\\ and\\ increased\\ pain\\.\\ at\\ this\\ time\\,\\ the\\ punch\\ biopsy\\ showed\\ no\\ malignant\\ changes\\.\\ no\\ further\\ treatment\\ of\\ the\\ mass\\ was\\ warranted\\,\\ but\\ the\\ patient\\ was\\ encouraged\\ to\\ follow\\ up\\ later\\ after\\ delivery\\.\ \(0\)\
\-\ the\\ images\\ below\\ demonstrate\\ a\\ large\\ subcutaneous\\ mass\\ on\\ the\\ left\\ lower\\ extremity\\.\ \(0\)\
\-\ neurofibromatosis\\ type\\ 1\ \(7\)\
\-\ differential\\ includes\\ leguis\\ syndrome\\,\\ mccune\\-albright\\ syndrome\\,\\ and\\ watson\\ syndrome\ \(0\)\
\-\ this\\ is\\ a\\ 21\\ year\\ old\\ g2p1\\ at\\ 28\\ weeks\\ who\\ presents\\ for\\ evaluation\\ of\\ a\\ large\\ mass\\ on\\ her\\ left\\ lateral\\ thigh\\.\\ the\\ mass\\ has\\ been\\ present\\ since\\ childhood\\ and\\ has\\ been\\ stable\\ in\\ size\\ for\\ many\\ years\\.\\ during\\ her\\ current\\ pregnancy\\,\\ the\\ mass\\ began\\ to\\ grow\\ slightly\\ and\\ increased\\ in\\ pain\\.\\ the\\ patient\\ endorses\\ pain\\ with\\ minor\\ trauma\\ that\\ lasts\\ for\\ days\\.\\ the\\ patient\\ denies\\ any\\ weakness\\ or\\ altered\\ sensation\\ in\\ the\\ leg\\.\\ no\\ night\\ sweats\\,\\ fevers\\,\\ chills\\,\\ or\\ weight\\ loss\\ noted\\ by\\ the\\ patient\\.\ \(0\)\
\-\ this\\ is\\ a\\ 22\\ year\\ old\\ g2p1\\ at\\ 28\\ weeks\\,\\ with\\ a\\ pmh\\ of\\ neurofibromatosis\\ type\\ 1\\,\\ who\\ presented\\ for\\ evaluation\\ of\\ a\\ large\\ mass\\ on\\ her\\ left\\ lateral\\ thigh\\.\\ \\ a\\ punch\\ biopsy\\ was\\ performed\\ to\\ rule\\ out\\ malignant\\ degeneration\\ into\\ a\\ peripheral\\ nerve\\ sheath\\ tumor\\.\\ punch\\ biopsy\\ of\\ the\\ lesion\\ revealed\\ a\\ plexiform\\ neurofibroma\\ without\\ malignant\\ changes\\.\\ malignant\\ peripheral\\ nerve\\ sheath\\ tumors\\ can\\ occur\\ from\\ large\\ plexiform\\ lesions\\.\\ patient\\'s\\ with\\ neurofibromatosis\\ type\\ 1\\ have\\ a\\ 10\\%\\ lifetime\\ risk\\ of\\ developing\\ one\\ of\\ these\\ tumors\\.\\ routine\\ surveillance\\ of\\ large\\ neurofibromas\\ especially\\ plexiform\\ neurofibromas\\ is\\ recommended\\.\\ plexiform\\ neurofibromas\\ can\\ grow\\ to\\ be\\ very\\ large\\ and\\ locally\\ invasive\\ which\\ can\\ lead\\ to\\ cosmetic\\ and\\ functional\\ concerns\\.\\ complete\\ resection\\ of\\ the\\ lesion\\ is\\ difficult\\ but\\ can\\ be\\ undertaken\\ if\\ if\\ the\\ lesion\\ causes\\ the\\ patient\\ functional\\ problems\\ or\\ cosmetic\\ concerns\\.\\ \ \(0\)\
\-\ source\\:\\ kevin\\ p\\.\\ boyd\\,\\ bruce\\ r\\.\\ korf\\,\\ amy\\ theos\\,\\ neurofibromatosis\\ type\\ 1\\,\\ journal\\ of\\ the\\ american\\ academy\\ of\\ dermatology\\,\\ volume\\ 61\\,\\ issue\\ 1\\,\\ 2009\\,\\ pages\\ 1\\-14\\,\\ issn\\ 0190\\-9622\\,\\ http\\:\\/\\/dx\\.doi\\.org\\/10\\.1016\\/j\\.jaad\\.2008\\.12\\.051\\.\ \(0\)\
\-\ \\(http\\:\\/\\/www\\.sciencedirect\\.com\\/science\\/article\\/pii\\/s0190962209004058\\)\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ plexiform\\:\\ 0\\.28376852905396727\ \(0\)\
\-\ neurofibromatosis\\:\\ 0\\.21365629428728672\ \(0\)\
\-\ large\\:\\ 0\\.19431511958321965\ \(0\)\
\-\ the\\:\\ 0\\.18056118563891174\ \(0\)\
\-\ hyperpigmented\\:\\ 0\\.17531798647095465\ \(0\)\
\-\ punch\\:\\ 0\\.16810120246071814\ \(0\)\
\-\ neurofibromas\\:\\ 0\\.164315430371293\ \(0\)\
\-\ malignant\\:\\ 0\\.15358285550483572\ \(0\)\
\-\ type\\:\\ 0\\.14453437397716917\ \(0\)\
\-\ her\\:\\ 0\\.13460305690342525\ \(0\)\
\-\ thigh\\:\\ 0\\.1271556429446522\ \(0\)\
\-\ for\\:\\ 0\\.11754408496687602\ \(0\)\
\-\ g2p1\\:\\ 0\\.1168786576473031\ \(0\)\
\-\ macules\\:\\ 0\\.1135074116215869\ \(0\)\
\-\ patient\\:\\ 0\\.1121218755968268\ \(0\)\
\-\ concerns\\:\\ 0\\.10842399924514835\ \(0\)\
\-\ cosmetic\\:\\ 0\\.10738165702896833\ \(0\)\
\-\ of\\:\\ 0\\.10119186017590015\ \(0\)\
\-\ routine\\:\\ 0\\.10010927807671376\ \(0\)\
\-\ mass\\:\\ 0\\.09875693276811606\ \(0\)\
\-\ grow\\:\\ 0\\.09850139386944741\ \(0\)\
\-\ to\\:\\ 0\\.09695326438490458\ \(0\)\
\-\ is\\:\\ 0\\.0944054000840228\ \(0\)\
\-\ surveillance\\:\\ 0\\.0941551018179365\ \(0\)\
\-\ follow\\:\\ 0\\.09291846983667244\ \(0\)\
\-\ biopsy\\:\\ 0\\.09061508711401789\ \(0\)\
\-\ can\\:\\ 0\\.09045049139119686\ \(0\)\
\-\ and\\:\\ 0\\.08904161113209473\ \(0\)\
\-\ size\\:\\ 0\\.08753006595413493\ \(0\)\
\-\ sheath\\:\\ 0\\.08570044341578176\ \(0\)\
\-\ functional\\:\\ 0\\.08454660276171305\ \(0\)\
\-\ degeneration\\:\\ 0\\.080144868557115\ \(0\)\
\-\ syndrome\\:\\ 0\\.0779330995107858\ \(0\)\
\-\ was\\:\\ 0\\.07508764002427083\ \(0\)\
\-\ lesions\\:\\ 0\\.0742423960647888\ \(0\)\
\-\ 28\\:\\ 0\\.07152509408783925\ \(0\)\
\-\ pregnancy\\:\\ 0\\.07052660667679646\ \(0\)\
\-\ leguis\\:\\ 0\\.068911375467781\ \(0\)\
\-\ kevin\\:\\ 0\\.068911375467781\ \(0\)\
\-\ boyd\\:\\ 0\\.068911375467781\ \(0\)\
\-\ korf\\:\\ 0\\.068911375467781\ \(0\)\
\-\ theos\\:\\ 0\\.068911375467781\ \(0\)\
\-\ recommended\\:\\ 0\\.06855320091060521\ \(0\)\
\-\ with\\:\\ 0\\.06750154819216171\ \(0\)\
\-\ amy\\:\\ 0\\.06584849817147173\ \(0\)\
\-\ extremities\\:\\ 0\\.06549347045245048\ \(0\)\
\-\ on\\:\\ 0\\.06507062242943674\ \(0\)\
\-\ in\\:\\ 0\\.06431737374559945\ \(0\)\
\-\ lateral\\:\\ 0\\.06415487193462582\ \(0\)\
\-\ up\\:\\ 0\\.06394600451468554\ \(0\)\
\-\ but\\:\\ 0\\.06392522326183804\ \(0\)\
\-\ http\\:\\ 0\\.06371400791134281\ \(0\)\
\-\ tumors\\:\\ 0\\.06338195125324597\ \(0\)\
\-\ caf\\:\\ 0\\.06198972913285818\ \(0\)\
\-\ bruce\\:\\ 0\\.06198972913285818\ \(0\)\
\-\ issn\\:\\ 0\\.06198972913285818\ \(0\)\
\-\ lesion\\:\\ 0\\.06197588926756678\ \(0\)\
\-\ peripheral\\:\\ 0\\.061626836775041445\ \(0\)\
\-\ care\\:\\ 0\\.06157817982553995\ \(0\)\
\-\ nerve\\:\\ 0\\.06148133353390074\ \(0\)\
\-\ ups\\:\\ 0\\.060612474849406996\ \(0\)\
\-\ watson\\:\\ 0\\.060612474849406996\ \(0\)\
\-\ boggy\\:\\ 0\\.05944802294463891\ \(0\)\
\-\ worms\\:\\ 0\\.05944802294463891\ \(0\)\
\-\ obgyn\\:\\ 0\\.05944802294463891\ \(0\)\
\-\ lasts\\:\\ 0\\.05944802294463891\ \(0\)\
\-\ academy\\:\\ 0\\.05944802294463891\ \(0\)\
\-\ has\\:\\ 0\\.059047698869531234\ \(0\)\
\-\ left\\:\\ 0\\.05879668070234259\ \(0\)\
\-\ counseled\\:\\ 0\\.05843932882365155\ \(0\)\
\-\ au\\:\\ 0\\.057549597553097714\ \(0\)\
\-\ lait\\:\\ 0\\.057549597553097714\ \(0\)\
\-\ lifetime\\:\\ 0\\.057549597553097714\ \(0\)\
\-\ no\\:\\ 0\\.056050393062824666\ \(0\)\
\-\ pages\\:\\ 0\\.05603373415357271\ \(0\)\
\-\ patches\\:\\ 0\\.05477181012376434\ \(0\)\
\-\ feel\\:\\ 0\\.05477181012376434\ \(0\)\
\-\ ophthalmologist\\:\\ 0\\.05477181012376434\ \(0\)\
\-\ endorses\\:\\ 0\\.05477181012376434\ \(0\)\
\-\ encouraged\\:\\ 0\\.05421199962257418\ \(0\)\
\-\ bag\\:\\ 0\\.05369082851448417\ \(0\)\
\-\ undertaken\\:\\ 0\\.05369082851448417\ \(0\)\
\-\ evaluation\\:\\ 0\\.052558226049994015\ \(0\)\
\-\ axilla\\:\\ 0\\.05231357423103298\ \(0\)\
\-\ spots\\:\\ 0\\.05231357423103298\ \(0\)\
\-\ changes\\:\\ 0\\.05208441813309635\ \(0\)\
\-\ weeks\\:\\ 0\\.05165017778260481\ \(0\)\
\-\ 9cm\\:\\ 0\\.05151768248872872\ \(0\)\
\-\ locally\\:\\ 0\\.05151768248872872\ \(0\)\
\-\ issue\\:\\ 0\\.05151768248872872\ \(0\)\
\-\ seek\\:\\ 0\\.051149122326264895\ \(0\)\
\-\ 10\\:\\ 0\\.050394480285297284\ \(0\)\
\-\ been\\:\\ 0\\.050210234468163334\ \(0\)\
\-\ if\\:\\ 0\\.050073509826782374\ \(0\)\
\-\ at\\:\\ 0\\.04882768412138296\ \(0\)\
\-\ who\\:\\ 0\\.0487494955967407\ \(0\)\
\-\ warranted\\:\\ 0\\.04820711136657302\ \(0\)\
\-\ advised\\:\\ 0\\.04796728217952208\ \(0\)\
\-\ maintain\\:\\ 0\\.04687057947220395\ \(0\)\
\-\ increased\\:\\ 0\\.04660277965387937\ \(0\)\
\-\ 2009\\:\\ 0\\.04647290950539032\ \(0\)\
\-\ pain\\:\\ 0\\.04625829146661286\ \(0\)\
\-\ plaque\\:\\ 0\\.04522589956706173\ \(0\)\
\-\ or\\:\\ 0\\.044971439073367245\ \(0\)\
\-\ this\\:\\ 0\\.04442019918910995\ \(0\)\
\-\ present\\:\\ 0\\.044222453161065566\ \(0\)\
\-\ lower\\:\\ 0\\.04403876737543116\ \(0\)\
\-\ sweats\\:\\ 0\\.04401467361265897\ \(0\)\
\-\ altered\\:\\ 0\\.04373995297844471\ \(0\)\
\-\ journal\\:\\ 0\\.04373995297844471\ \(0\)\
\-\ 61\\:\\ 0\\.04373995297844471\ \(0\)\
\-\ childhood\\:\\ 0\\.04360625064064067\ \(0\)\
\-\ moderately\\:\\ 0\\.043474873679145806\ \(0\)\
\-\ various\\:\\ 0\\.043093919773326377\ \(0\)\
\-\ neurofibroma\\:\\ 0\\.04261414046677678\ \(0\)\
\-\ axillary\\:\\ 0\\.042385214314884075\ \(0\)\
\-\ dermatology\\:\\ 0\\.04216302227075245\ \(0\)\
\-\ developing\\:\\ 0\\.0412368861833256\ \(0\)\
\-\ treatment\\:\\ 0\\.04105275307649475\ \(0\)\
\-\ subcutaneous\\:\\ 0\\.04104563584459925\ \(0\)\
\-\ source\\:\\ 0\\.04104563584459925\ \(0\)\
\-\ delivery\\:\\ 0\\.04049932666046296\ \(0\)\
\-\ minor\\:\\ 0\\.04049932666046296\ \(0\)\
\-\ undergo\\:\\ 0\\.04024030751783141\ \(0\)\
\-\ rapid\\:\\ 0\\.0400724342785575\ \(0\)\
\-\ began\\:\\ 0\\.0400724342785575\ \(0\)\
\-\ chills\\:\\ 0\\.039210424084547245\ \(0\)\
\-\ invasive\\:\\ 0\\.039210424084547245\ \(0\)\
\-\ which\\:\\ 0\\.0391875203091243\ \(0\)\
\-\ pmh\\:\\ 0\\.03899145266927733\ \(0\)\
\-\ night\\:\\ 0\\.03870902781728081\ \(0\)\
\-\ potential\\:\\ 0\\.03850392965637998\ \(0\)\
\-\ lead\\:\\ 0\\.038370227318575936\ \(0\)\
\-\ fevers\\:\\ 0\\.038045972179779154\ \(0\)\
\-\ volume\\:\\ 0\\.03785789645126164\ \(0\)\
\-\ physician\\:\\ 0\\.03779623092611678\ \(0\)\
\-\ current\\:\\ 0\\.037735064722443555\ \(0\)\
\-\ problems\\:\\ 0\\.03737811714471205\ \(0\)\
\-\ regular\\:\\ 0\\.037205775413807846\ \(0\)\
\-\ sensation\\:\\ 0\\.036926998948687714\ \(0\)\
\-\ american\\:\\ 0\\.03676454139960686\ \(0\)\
\-\ difficult\\:\\ 0\\.035762547043919624\ \(0\)\
\-\ below\\:\\ 0\\.035486150911222133\ \(0\)\
\-\ be\\:\\ 0\\.03496033102858634\ \(0\)\
\-\ denies\\:\\ 0\\.03475385292293227\ \(0\)\
\-\ eye\\:\\ 0\\.03447180472496492\ \(0\)\
\-\ 21\\:\\ 0\\.03443235823908333\ \(0\)\
\-\ there\\:\\ 0\\.03429129432889347\ \(0\)\
\-\ rule\\:\\ 0\\.03419990959475995\ \(0\)\
\-\ stable\\:\\ 0\\.03408631369651006\ \(0\)\
\-\ especially\\:\\ 0\\.03408631369651006\ \(0\)\
\-\ many\\:\\ 0\\.03397440076248251\ \(0\)\
\-\ 22\\:\\ 0\\.03393746188750323\ \(0\)\
\-\ full\\:\\ 0\\.033683827058691745\ \(0\)\
\-\ slightly\\:\\ 0\\.03361289710205516\ \(0\)\
\-\ includes\\:\\ 0\\.03350773552136618\ \(0\)\
\-\ complications\\:\\ 0\\.03300282703501634\ \(0\)\
\-\ 18\\:\\ 0\\.03265289569797568\ \(0\)\
\-\ specific\\:\\ 0\\.03265289569797568\ \(0\)\
\-\ change\\:\\ 0\\.03265289569797568\ \(0\)\
\-\ causes\\:\\ 0\\.03256020760405205\ \(0\)\
\-\ leg\\:\\ 0\\.03252956259293328\ \(0\)\
\-\ occur\\:\\ 0\\.031690975626622986\ \(0\)\
\-\ tender\\:\\ 0\\.03150177828013124\ \(0\)\
\-\ weakness\\:\\ 0\\.03144858098365311\ \(0\)\
\-\ could\\:\\ 0\\.03134329726012623\ \(0\)\
\-\ since\\:\\ 0\\.031213723158993324\ \(0\)\
\-\ extremity\\:\\ 0\\.031035974137320857\ \(0\)\
\-\ very\\:\\ 0\\.030911523466173225\ \(0\)\
\-\ later\\:\\ 0\\.030837825468142267\ \(0\)\
\-\ risk\\:\\ 0\\.030789089912769976\ \(0\)\
\-\ complete\\:\\ 0\\.030205029038005964\ \(0\)\
\-\ weight\\:\\ 0\\.03004927125422524\ \(0\)\
\-\ palpation\\:\\ 0\\.02905987212426671\ \(0\)\
\-\ back\\:\\ 0\\.02873837744041778\ \(0\)\
\-\ showed\\:\\ 0\\.0287014385654385\ \(0\)\
\-\ out\\:\\ 0\\.02832410999237817\ \(0\)\
\-\ revealed\\:\\ 0\\.02825432672584896\ \(0\)\
\-\ further\\:\\ 0\\.02806568165870586\ \(0\)\
\-\ differential\\:\\ 0\\.027998234917057857\ \(0\)\
\-\ any\\:\\ 0\\.02784864616986395\ \(0\)\
\-\ resection\\:\\ 0\\.027621685346254657\ \(0\)\
\-\ during\\:\\ 0\\.027293539270868545\ \(0\)\
\-\ days\\:\\ 0\\.027278263259837114\ \(0\)\
\-\ year\\:\\ 0\\.026559397337458834\ \(0\)\
\-\ primary\\:\\ 0\\.026496118536578343\ \(0\)\
\-\ years\\:\\ 0\\.02641400919684237\ \(0\)\
\-\ loss\\:\\ 0\\.02625242047114285\ \(0\)\
\-\ time\\:\\ 0\\.02554093167262458\ \(0\)\
\-\ old\\:\\ 0\\.025506215207506566\ \(0\)\
\-\ performed\\:\\ 0\\.025492586004367632\ \(0\)\
\-\ presented\\:\\ 0\\.02512804285070931\ \(0\)\
\-\ trauma\\:\\ 0\\.02502542110049126\ \(0\)\
\-\ one\\:\\ 0\\.024671436109003582\ \(0\)\
\-\ these\\:\\ 0\\.02433329921766794\ \(0\)\
\-\ consistent\\:\\ 0\\.02336475496081816\ \(0\)\
\-\ bilateral\\:\\ 0\\.023158520606054805\ \(0\)\
\-\ upper\\:\\ 0\\.023026991138934725\ \(0\)\
\-\ into\\:\\ 0\\.02290626278346463\ \(0\)\
\-\ noted\\:\\ 0\\.02284661453877912\ \(0\)\
\-\ without\\:\\ 0\\.022728712715790373\ \(0\)\
\-\ tumor\\:\\ 0\\.022538924849768254\ \(0\)\
\-\ demonstrate\\:\\ 0\\.022401649299746213\ \(0\)\
\-\ it\\:\\ 0\\.022057515948803813\ \(0\)\
\-\ exam\\:\\ 0\\.02169186900846662\ \(0\)\
\-\ have\\:\\ 0\\.02152615740170418\ \(0\)\
\-\ multiple\\:\\ 0\\.021076588582135028\ \(0\)\
\-\ after\\:\\ 0\\.020903994424876\ \(0\)\
\-\ presents\\:\\ 0\\.02072884051367722\ \(0\)\
\-\ images\\:\\ 0\\.01993230754350612\ \(0\)\
\-\ that\\:\\ 0\\.01869973841416479\ \(0\)\
\-\ by\\:\\ 0\\.01829880115280165\ \(0\)\
\-\ as\\:\\ 0\\.017311054777152047\ \(0\)\
\-\ from\\:\\ 0\\.01711379056528525\ \(0\)\
\-\ an\\:\\ 0\\.016477730737578373\ \(0\)\
